

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Randall K. Ribaud and Michael Shields

Application No. _____

Filed: Herewith

Confirmation No. _____

For: BETA2 MICROGLOBULIN FUSION
PROTEINS AND HIGH AFFINITY
VARIANTS

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 4239-67022

MAIL STOP PATENT APPLICATION
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
FOR CONTINUING APPLICATIONS

Listed on the accompanying form PTO-1449 are several English-language and/or non-English-language documents. Applicants respectfully request that such documents be listed as references cited on the issued patent.

The present application relies upon U.S. Patent Application No. 09/719,243, which was filed March 19, 2001, for an earlier filing date under 35 U.S.C. § 120. Furthermore, documents listed on the accompanying form PTO-1449 were disclosed to or cited by the Patent Office in the earlier U.S. application.

Copies of the documents listed on the accompanying form PTO-1449 that were cited by applicants in the earlier application need not be sent to the Patent Office pursuant to 37 C.F.R.

§ 1.98. However, applicants will furnish the Patent Office with such copies upon request.

Copies of documents listed on the accompanying form PTO-1449 that were cited by the Patent Office in the earlier application are enclosed.


Please charge any additional fees that may be required in connection with filing this Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 02-4550.

A duplicate copy of this sheet is enclosed.

The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sherree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Attorney Docket Number	4239-67022
				Application Number	
				Filing Date	
				First Named Inventor	Ribaudo
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
FOREIGN PATENT DOCUMENTS					
Examiner's Initials*	Cite No. (optional)	Number	Date	Country	
		WO 97/24446	10.07.97	WIPO	
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS			
		Bjorkman et al., "Structure of the Human Class I Histocompatibility Antigen, HLA-A2," <i>Nature</i> 329:506-512 (1987).			
		Freeman et al., "Murine B7-2, an Alternative CTLA4 Counter-Receptor that Costimulates T Cell Proliferation and Interleukin 2 Production," <i>J. Exp. Med.</i> 178:2185-2192 (1993).			
		Freeman et al., "Cloning of B7-2: A CTLA-4 Counter-Receptor that Costimulates Human T Cell Proliferation," <i>Science</i> 262:909-911 (1993).			
		Fukazawa et al., "The Effect of Mutant β_2 -Microglobulins on the Conformation of HLA-B27 Detected by Antibody and by CTL," <i>J. Immunol.</i> 153:3543-3550 (1994).			
		Gerstmayer et al., "Costimulation of T Cell Proliferation by a Chimeric B7-2 Antibody Fusion Protein Specifically Targeted to Cells Expressing the <i>erbB2</i> Proto-Oncogene," <i>J. Immunol.</i> 158:4584-4590 (1997).			
		Liu, "The Immunologist's Grail: Vaccines that Generate Cellular Immunity," <i>Proc. Natl. Acad. Sci. USA</i> 94:10496-10498 (1997).			
		Mottez et al., "Cells Expressing a Major Histocompatibility Complex Class I Molecule with a Single Covalently Bound Peptide Are Highly Immunogenic," <i>J. Exp. Med.</i> 181:493-502 (1995).			
		Rock et al., "Peptide-Priming of Cytolytic T Cell Immunity in Vivo Using β_2 -Microglobulin as an Adjuvant," <i>J. Immunol.</i> 150:1244-1252 (1993).			
		Shields et al., "The Effect of Human β_2 -Microglobulin on Major Histocompatibility Complex I Peptide Loading and the Engineering of a High Affinity Variant," <i>J. Biol. Chem.</i> 273:28010-28018 (1998).			
		Shields et al., "Characterization of the Interactions between MHC Class I Subunits: A Systematic Approach for the Engineering of Higher Affinity Variants of β_2 -Microglobulin," <i>J. Immunol.</i> 160:2297-2307 (1998).			
		Uger et al., "Creating CTL Targets with Epitope-Linked β -Microglobulin Constructs," <i>J. Immunol.</i> 160:1599-1605 (1998).			

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-67022
Application Number	
Filing Date	
First Named Inventor	Ribauda
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		5,434,131	7/18/1995	Linsley et al.
		5,521,288	5/28/1996	Linsley et al.
		5,529,921	6/25/1996	Peterson et al.
		5,574,205	11/12/1996	Kucherlapati et al.
		5,580,756	12/3/1996	Linsley et al.
		5,582,831	12/10/1996	Shinitzky
		5,698,679	12/16/1997	Nemazee
		5,712,149	1/27/1998	Roberts
		5,733,550	3/31/1998	Rock
		6,183,734	2/6/2001	Chen et al.
		6,451,305	9/17/2002	Boussiotis et al.
		US 2002/0123108 A1	9/5/2002	Edwards et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		0 733 373 A2	25.09.96	Europe
		WO 91/16924	14.11.91	WIPO
		WO 94/24290	27.10.94	WIPO

EXAMINER
SIGNATURE:DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.